Viking Therapeutics, Inc. (VKTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 01:09PM EDT. Market open.
| Previous close | 63.85 |
| Open | 64.55 |
| Bid | 67.03 x 100 |
| Ask | 67.43 x 200 |
| Day's range | 63.51 - 67.58 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 6,469,075 |
| Market cap | 7.39B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 113.80 |
ZacksViking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
ZacksViking (VKTX) to Report Q1 Earnings: What's in the Cards?
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
© 2024 Yahoo. All rights reserved.